Environmental stimuli that are reliably associated with the effects of many
abused drugs, especially stimulants such as cocaine, can produce craving a
nd relapse in abstinent human substance abusers(1-4). In animals, such cues
can induce and maintain drug-seeking behaviour and also reinstate drug-see
king after extinction(5-7). Reducing the motivational effects of drug-relat
ed cues might therefore be useful in the treatment of addiction(3). Converg
ing pharmacological(8,9), human post-mortem(10) and genetic(11) studies imp
licate the dopamine D-3 receptor(12) in drug addiction. Here we have design
ed BP 897, the first D-3-receptor-selective agonist, as assessed in vitro w
ith recombinant receptors and in vivo with mice bearing disrupted D-3-recep
tor genes. BP 897 is a partial agonist in vitro and acts in vivo as either
an agonist or an antagonist. We show that BP 897 inhibits cocaine-seeking b
ehaviour that depends upon the presentation of drug-associated cues, withou
t having any intrinsic, primary rewarding effects. Our data indicate that c
ompounds like BP 897 could be used for reducing the drug craving and vulner
ability to relapse that are elicited by drug-associated environmental stimu
li.